Explore /
Poster
/ Outcome of BRCA 1/2-Mutated (BRCA+) and triple-negative, BRCA wild type (BRCA-wt) breast cancer patients in a phase I study of single-agent veliparib (V).

Outcome of BRCA 1/2-Mutated (BRCA+) and triple-negative, BRCA wild type (BRCA-wt) breast cancer patients in a phase I study of single-agent veliparib (V).

Authors

Shalu Pahuja

University of Pittsburgh Cancer Institute, Pittsburgh, PA

Shalu Pahuja , Jan Hendrik Beumer , Leonard Joseph Appleman , Hussein Abdul-Hassan Tawbi , Ronald G. Stoller , James J. Lee , Yan Lin , Brian Kiesel , Jing Yu , Antoinette R. Tan , Chandra Prakash Belani , Helen K. Chew , Agustin A. Garcia , Robert Morgan , Alice P. Chen , Vincent L. Giranda , Stacie Peacock Shepherd , Edward Chu , Shannon Puhalla

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2014 Breast Cancer Symposium

Session Type

Poster Session

Session Title

General Poster Session B: Risk Assessment, Prevention, Early Detection, Screening, and Systemic Therapy

Track

Systemic Therapy,Risk Assessment, Prevention, Early Detection, and Screening

Sub Track

Triple-Negative

Clinical Trial Registration Number

NCT00892736

Citation

J Clin Oncol 32, 2014 (suppl 26; abstr 135)

DOI

10.1200/jco.2014.32.26_suppl.135

Abstract #

135

Poster Bd #

Abstract Disclosures

Similar Posters

Poster

2012 ASCO Annual Meeting

$A phase I study of chronically dosed, single-agent veliparib (ABT-888) in patients (pts) with either BRCA 1/2-mutated cancer (BRCA+), platinum-refractory ovarian cancer, or basal-like breast cancer (BRCA-wt).$